Hersi Ahmad, Wyse D George
The Libin Cardiovascular Institute of Alberta, University of Calgary, Room G009, 3330 Hospital Drive NW,Calgary AB, T2N 4N1, Canada.
Curr Cardiol Rep. 2006 Sep;8(5):323-9. doi: 10.1007/s11886-006-0070-6.
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia encountered in clinical practice. The management of AF remains associated with many challenges that make its treatment a vexing problem. However, in recent years extraordinary progress has been made in the understanding and management of AF. In general, antiarrhythmic drugs for rhythm control have been disappointing. We have a better understanding of pharmacologic cardioversion and this has led to newer strategies, such as intermittent therapy. Several studies have been completed comparing pharmacologic rhythm control with pharmacologic heart rate control. There is also an emerging body of evidence concerning the value of adjunctive drug use for rhythm control using drugs that would not usually be considered to be antiarrhythmic. Finally, antithrombotic therapy is an increasingly important part of the medical management of AF. This article summarizes the results of many of the recent publications and their clinical implications concerning management of this common rhythm disorder.
心房颤动(AF)是临床实践中最常见的持续性快速心律失常。房颤的管理仍然面临许多挑战,使其治疗成为一个棘手的问题。然而,近年来在房颤的认识和管理方面取得了非凡的进展。一般来说,用于节律控制的抗心律失常药物效果并不理想。我们对药物复律有了更好的理解,这导致了更新的策略,如间歇治疗。已经完成了几项比较药物节律控制和药物心率控制的研究。也有越来越多的证据表明,使用通常不被认为是抗心律失常药物辅助控制节律具有价值。最后,抗栓治疗在房颤的药物管理中越来越重要。本文总结了许多近期出版物的结果及其对这种常见节律紊乱管理的临床意义。